Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE , a randomized, double‐blind, placebo‐controlled study
Open accessThe DOI matches its Crossref record.
Abstract
This multicenter, double‐blind, placebo‐controlled study examined the efficacy and safety of ipragliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in combination with metformin in Japanese patients with type 2 diabetes mellitus ( T2DM ). Patients were randomized in a 2 : 1 ratio to 50 mg ipragliflozin (n = 112) or placebo (n = 56) once daily for 24 weeks, followed by a 28‐week open‐label extension in which all patients received 50 or 100 mg ipragliflozin, while continuing metformin. The primary outcome was the change in glycated haemoglobin ( HbA1c ) from baseline to week 24. HbA1c decreased significantly in the ipragliflozin group (−0.87%; adjusted mean difference from placebo: −1.30%; p < 0.001). The overall incidence of treatment‐emergent adverse events was similar in both groups, although pollakiuria and constipation were more common in the ipragliflozin group; thus, ipragliflozin significantly improved glycaemic control and reduced body weight without major safety issues in Japanese patients with T2DM .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Scheen, A. J. (2015) · Drugs · doi:10.1007/s40265-014-0337-y · Cited by 554
Toyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M. J., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13648 · Cited by 330
Cai, X., Yang, W., Gao, X., Chen, Y., Zhou, L., Zhang, S., Han, X., & Ji, L. (2018) · Obesity · doi:10.1002/oby.22066 · Cited by 181
Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD
Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., Kubotsu, Y., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1696 · Cited by 153
Imprialos, K. P., Sarafidis, P. A., & Karagiannis, A. I. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000719 · Cited by 71
“[92] conducted a 24-week study of 50mg of ipragliflozin vs placebo as additional therapy to metformin in Japanese patients with type 2 diabetes mellitus, and observed an insignificant decrease of SBP/DBP vs baseline ( 1.”
Method
Metadata
- Authors
- Kashiwagi, A., Kazuta, K., Goto, K., Yoshida, S., Ueyama, E., & Utsuno, A.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2014-07-31
- Volume
- 17
- Issue
- 3
- Pages
- 304-308
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2092380707
- Cited by
- 102
- References
- 0
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE , a randomized, double‐blind, placebo‐controlled study. https://app.cochat.ai/papers/10.1111/dom.12331
- The paper
- Kashiwagi, A., Kazuta, K., Goto, K., Yoshida, S., Ueyama, E., & Utsuno, A. (2015). Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE , a randomized, double‐blind, placebo‐controlled study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12331
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.